PTO/SB/08s (06-03.)
Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Pages,Columns,Lines

where Relevant Passages or Relevant

Figures Appear

Name of Patentee or

Applicant of cited

Document

Under the Paperwork Reduction Act of 1995, no persons a o a collection of information unless it contains a valid OMB control number. Application Number

Filing Date

INFORMATION DISCLOSURE				First Named Inventor Bernhard GLEICH					Т		
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)				Art Unit						Т	
(Not for submission under 37 CFR 1.99)				Examiner Na	Examiner Name						_
				Attorney Doc	ket Numb	er	PHUS040141US	US2		_	
											_
U.S.PATENTS Remove									Τ		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		į		
	1	4631481		1986-12-23	Young, et al.		all				
	2	4771243		1988-09-13	Vreugdenhil, et al.		all				
	3	62944972	B1	2001-09-25	Jesmanowicz, et al.		all				
	4	6627003	B2	2003-09-30	Hayworth,	et al.		all			
If you wis	h to a	dd additional U.S. Paten	t citatio	n information pl	ease click	the Ac	ld button.		Add		Т
U.S.PATENT APPLICATION PUBLICATIONS Remove											
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				
	1	20030075243	A1	2003-04-24	Hayworth, et al.		all				
If you wis	h to a	dd additional U.S. Publis	hed Ap	plication citation	n informati	on ple	ase click the Add				
FOREIGN PATENT DOCUMENTS Remove											

Kind Publication

Code⁴ Date

Examiner Cite

No

Foreign Document

Number³

Country

Code² i

Application Number | Filing Date | STATEMENT BY APPLICANT (Not for submission under 37 GFR 1.99) | Examiner Name | Attorney Codet Number | PHJS940161USZ

NON-PATENT LITERATURE DOCUMENTS							Remove	
If you wish to add additional Foreign Patent Document citation information please click the Add button Add								
	3	EP 1 260 827	EP	A2	2002-11-27	Mitsubishi	all	
	2	EP 1 193 507	EP	A2	2002-04-03	General Electric Co.	all	
	1	EP 0 737 867	EP EP	A1	1996-10-16	Picker International	all	

If you wish to add additional non-patent literature document citation information please click the Add button Add

Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind. Codes of UBPTO Patent Documents at swer, UBPTO_QDV or MPEP 061.04. 2 Enter office that issued the document, by the Nov-lettor code (WIPO Standard ST3.). 3 For Laprances patent of counters, the ancidation of the parent of the Empirer smart process the small amount of the Capture process the small partner of the patent for the Empirer small process are small called on the document under WIPO Standard ST.16 if possible. 3 Applicant is to place a check mark here if Empirel Integrate Processible on additional.

Application Number Filing Date STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Application Number Filing Date First Named Inventor Benhard GLEICH Art Unit Examiner Name Attorney Docket Number | PHJS040141US2

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98	to make the	appropriate	selection(s	s):
---------------	----------	----------	-------------	-------------	-------------	-----

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 197(eVI).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(eV).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Thomas M. Lundin/	Date (YYYY-MM-DD)	2006-08-30
Name/Print	Thomas M. Lundin	Registration Number	48979

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant Affice, U.S. Department of Commence, P. 0. Bot 1450, Alexandria, V.32.11.450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.3.2.11.450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicide is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually the principal purpose and for examines your submission, which may visually intermediate or of extended now about the principal purpose.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuint to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs and of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public of the record via yet for disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public of the record via fifed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.